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Purpose: Plasma adiponectin concentrations are inversely related with metabolic 
syndrome (MetS), and MetS is associated with increased risk for heart failure 
(HF). However, the relationship between adiponectin and MetS in HF remains un-
determined. Therefore, we tested whether MetS was associated with the degree of 
plasma adiponectin concentrations in HF patients. Materials and Methods: One 
hundred twenty eight ambulatory HF patients with left ventricular ejection fraction 
of <50% (80 males, 61.8±11.9 years old) were enrolled for this cross-sectional 
study. Echocardiographic measurements were performed, and plasma concentra-
tions of adiponectin, lipoproteins, apolipoproteins (apoB, apoA1) and high sensi-
tive C-reactive protein (hsCRP) were measured. Results: Adiponectin concentra-
tions in HF patients with MetS (n=43) were significantly lower than those without 
MetS (n=85) (9.7±7.0 vs. 15.8±10.9 µg/mL, p=0.001). Higher concentrations of 
apoB (p=0.017), apoB/A1 ratio (p<0.001), blood urea nitrogen (p=0.034), creati-
nine (p=0.003), and fasting insulin (p=0.004) were observed in HF patients with 
MetS compared with those without MetS. In HF patients with MetS, adiponectin 
concentrations were negatively correlated with hsCRP (r=-0.388, p=0.015) and 
positively correlated with the ratio of early mitral inflow velocity to early diastolic 
mitral annular velocity, E/E' (r=0.399, p=0.015). There was a significant trend to-
wards decreased adiponectin concentrations with an increasing number of compo-
nents of MetS (p for trend=0.012). Conclusion: Our study demonstrated that adi-
ponectin concentrations decreased in HF patients with MetS, and that relationship 
between adiponectin, inflammation and abnormal diastolic function, possibly lead-
ing to the progression of HF.
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INTRODUCTION
Adiponectin, an adipocyte-derived cytokine, has been shown to decrease in obesi-
ty1 and in patients with type 2 diabetes mellitus.2 Furthermore, adiponectin concen-Hoyoun Won, et al.
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ria (WHO Western Pacific Region obesity criteria) as having 
three or more of the following components13: 1) waist cir-
cumference ≥90 cm for men or ≥80 cm for women; 2) tri-
glycerides ≥150 mg/dL; 3) high-density lipoprotein (HDL)-
cholesterol <40 mg/dL for men or <50 mg/dL for women; 
4) high blood pressure (systolic blood pressure ≥ 130 mm 
Hg or diastolic pressure ≥85 mm Hg) or current use of anti-
hypertensive medications; 5) fasting glucose ≥110 mg/dL or 
receiving treatment for diabetes. MetS severity was scored 
on a scale of 1 to 5 according to the number of MetS com-
ponents.
Biochemical analysis
Venous blood samples were collected from the forearm after 
fasting overnight for a minimum of eight hours. Serum total 
cholesterol and lipoproteins were measured by commercially 
available kits (Choongwae, Seoul, Korea). Serum triglycer-
ide was measured with a total glycerol test kit (Roche, Basel, 
Switzerland). Fasting serum glucose levels were measured 
by using a Beckman Glucose Analyzer (Beckman Instru-
ments, Irvine, CA, USA). Fasting serum insulin concentra-
tions were measured with an immunoradiometric assay and 
a gamma counter (Hewlett Packard, Meriden, CT, USA). 
The plasma adiponectin was measured using an enzyme-
linked immunoassay (Linco Research, St. Charles, MO, 
USA). The minimal detection limit for adiponectin was 
0.78 µg/mL, and the intra- and interassay coefficients of vari-
ation were both <15%. Apolipoprotein (apo) A1 and apoB 
were measured by immunoturbidometry (Hitachi autoana-
lyzer, model 705, Tokyo, Japan). All other chemistries were 
examined by enzymatic methods using a Hitachi 7600-110, 
automated chemistry analyzer (Hitachi, Tokyo, Japan). The 
homeostasis model of insulin resistance (HOMA-IR) was 
calculated using the equation16; HOMA-IR=fasting insulin 
(μIU/mL)×fasting glucose (mg/dL)/405.
Echocardiographic measurement
Standard two-dimensional echocardiography was performed 
in all patients. LVEF was calculated by the modified Qui-
nones method. Left atrial volume was calculated by the 
prolate ellipsoid method. The left atrial volume index (LAVI) 
was calculated by left atrial volume divided by body sur-
face area. Peak velocity of early diastolic filling (E) was ob-
tained from mitral inflow velocities by pulsed wave Dop-
pler at apical four chamber view. Peak early diastolic velocity 
of mitral annulus (E’) was obtained from the tissue Doppler 
imaging of the septal mitral annulus.　　
trations correlate negatively with C reactive protein (CRP), 
interleukin 6 and tumor necrosis factor-α.3,4 Decreased adi-
ponectin concentrations are also related to the presence of 
coronary artery disease5,6 and hypertension.7 Therefore, adi-
ponectin has been suggested to have anti-inflammatory, anti-
diabetic and anti-atherogenic effects. However, adiponectin 
concentrations are paradoxically high in patients with heart 
failure (HF).8-10 Moreover, high circulating concentrations of 
adiponectin are associated with mortality, severity and cardi-
ac cachexia in patients with HF.11,12
Metabolic syndrome (MetS), which consists of hyperten-
sion, impaired glucose tolerance, obesity and dyslipidemia, 
has been reported to be associated with an increased risk of 
HF,13 and it is also associated with an increased risk of death 
in HF patients.14 To date, the relationship between adiponec-
tin and MetS in patients with HF has not yet been investigat-
ed. Therefore, we examined to test how the degree of plas-
ma adiponectin concentrations would be changed according 
to the presence of MetS in HF patients.
MATERIALS AND METHODS
　　　
Study subjects
This cross-sectional study included 128 ambulatory HF pa-
tients from the HF outpatient clinic at Severance Cardiovas-
cular Hospital. Inclusion criteria were: 1) clinical diagnosis 
of HF with left ventricular ejection fraction (LVEF) <50% as 
documented by echocardiography, 2) age under 80 years 
old, and 3) stable HF on medication for at least three months 
before inclusion. We excluded patients with 1) diagnosis of 
HF with preserved ejection fraction (≥50%) and 2) diagno-
sis of acute myocardial infarction three months prior to inclu-
sion. Etiology of HF, comorbidities and medications were 
obtained from hospital database. Chronic kidney disease 
was defined as an estimated glomerular filtration rate (eGFR) 
of less than 60 mL/min/1.73m2. The eGFR was estimated 
by using the simplified Modification of Diet in Renal Dis-
ease study equation.15
Patient data were collected in accordance with the institu-
tional ethics guidelines. All patients gave written informed 
consent and study approval was obtained from the internal 
review board of Severance Hospital. 
Definition of MetS
MetS was defined according to the updated National Cho-
lesterol Education Program/Adult Treatment Panel III crite-Adiponectin and Metabolic Syndrome in Heart Failure
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Triglyceride, HDL-cholesterol, apoB, apoB/A1 ratio and al-
bumin had significant correlations with plasma adiponectin 
Statistical analysis
SPSS version 17.0 (SPSS Inc., Chicago, IL, USA) was used 
for statistical analysis. Continuous variables were described 
using mean±standard deviations or medians, and interquar-
tile ranges and categorical variables were described using 
numbers or percentages. Triglyceride, hsCRP, insulin and 
HOMA-IR were logarithmically transformed for analysis. 
Differences in variables between the groups were evaluated 
using Student’s t-test or the Mann-Whitney U test and us-
ing analysis of covariance (ANCOVA) for adjusting other 
variables. The χ2 test was used for categorical data. The cor-
relation between adiponectin and both laboratory and echo-
cardiographic parameters was evaluated using Spearman’s 
correlation. ANOVA was used to compare adiponectin con-
centrations between groups based on the number of MetS 
components. A p value of <0.05 was considered statistically 
significant. 
 
RESULTS
 
Baseline characteristics
Table 1 presents the baseline characteristics of all HF pa-
tients. This study consisted of 128 HF patients (80 of whom 
were male) with a mean age of 61.8±11.9 years. Most of the 
subjects were in New York Heart Association functional 
class I (47.7%) and II (52.3%). Coronary artery disease was 
the most common etiology of HF (46.0%). Hypertension 
(39.8%), dyslipidemia (25.8%), and atrial fibrillation (21.8%) 
were common prevalent comorbidities. Medical treatment 
for all subjects consisted of diuretics (65.7%), digitalis 
(24.2%), angiotensin converting enzyme inhibitors and/or 
angiotensin II receptor blockers (73.4%), β-blockers (56.3%) 
and calcium channel blockers (65.7%). The mean LVEF was 
34.8±13.1% among all HF patients.  
Adiponectin and its correlations with variables in HF 
patients
Plasma adiponectin concentrations were correlated with 
body mass index (BMI) (r=-0.352, p<0.001), waist circum-
ference (r=-0.336, p<0.001), triglyceride (r=-0.402, p<0.001), 
HDL-cholesterol (r=0.359, p<0.001), apoB (r=-0.265, 
p=0.025), apoB/A1 ratio (r=-0.273, p=0.021), hemoglobin 
(r=-0.260, p=0.003), albumin (r=-0.193, p=0.029) and fast-
ing glucose (r=-0.185, p=0.037) (Table 2). However, no asso-
ciation was found between adiponectin and hsCRP, nor was 
adiponectin correlated with fasting insulin and HOMA-IR. 
Table 1. Baseline Characteristics for All HF Patients
n=128
Demographics
    Age (yrs)   61.8±11.9
    Male, n (%) 80 (62.5)
    BMI (kg/m
2) 23.7±3.7
Etiologies of HF
    CAD, n (%) 59 (46.0)
    Cardiomyopathy, n ( %) 51 (39.8)
    Valvular diseases, n (%) 9 (7.0)
    Others, n (%)  9 (7.0)
Comorbidities
    Hypertension, n (%) 51 (39.8)
    Dyslipidemia, n (%) 33 (25.8)
    Atrial fibrillation, n (%) 28 (21.8)
    Diabetes, n (%) 22 (17.2)
    CKD, n (%) 13 (10.2)
Medical treatment
    Diuretics, n (%) 84 (65.7)
    Digitalis, n (%) 31 (24.2)
    ACEis/ARBs, n (%) 94 (73.4)
    β-blockers, n (%) 72 (56.3)
    CCBs, n (%) 84 (65.7)
Echocardiograhic parameters
    LVEF (%) 34.8±13.1
HF, heart failure; BMI, body mass index; CAD, coronary artery disease; 
CKD, chronic kidney disease; ACEis, angiotension converting enzyme 
inhibitors; ARBs, angiotension II receptor blockers; CCBs, calcium channel 
blockers; LVEF, left ventricular ejection fraction.
Values are expressed as mean±SD. 
Table 2. Factors Correlated with Adiponectin Concentra-
tions in All HF Patients
Variables Coefficient p value
BMI (kg/m
2) -0.352 <0.001
Waist circumference (cm) -0.336 <0.001
Triglyceride (mg/dL)*
,† -0.402 <0.001
HDL-cholesterol (mg/dL)*  0.359 <0.001
ApoB (mg/L)* -0.265   0.025
ApoB/A1* -0.273   0.021
Hemoglobin (g/dL) -0.260   0.003
Albumin (mg/dL)* -0.193   0.029
Glucose, fasting (mg/dL) -0.185   0.037
LAVI (mL/m
2)  0.197   0.026
E/E’  0.217   0.021
HF, heart failure; BMI, body mass index; HDL, high density lipoprotein; 
Apo, apolipoprotein; LAVI, left atrial volume index; E/E’, early mitral inflow 
velocity to early diastolic mitral annular velocity ratio. 
*Significant variables after adjustment for age, sex and BMI.
†Triglyceride was log-transformed for analysis.Hoyoun Won, et al.
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(p<0.001), and chronic kidney disease (p<0.001) were sig-
nificantly higher in HF patients with MetS than in those 
without MetS.
We compared the concentrations of adiponectin, lipopro-
teins, apolipoproteins and other laboratory parameters be-
tween the two groups (Table 4). Serum concentrations of 
glucose, triglyceride and HDL-cholesterol were differed 
significantly between the two groups, while serum total 
cholesterol levels were similar. Concentrations of adiponec-
tin were significantly lower in HF patients with MetS (9.7± 
7.0 μg/mL) than in HF patients without MetS (15.8±10.9 
μg/mL) (p=0.001). Adiponectin level was also lower in HF 
with MetS than with HF without MetS after adjusting age 
and BMI in ANCOVA analysis (p=0.006). Higher concentra-
tions of blood urea nitrogen (p=0.034), creatinine (p=0.003), 
hsCRP (p=0.019), fasting glucose (p<0.001), fasting insulin 
(p<0.001), and HOMA-IR (p<0.001) were observed in HF 
concentrations after adjusting for age, gender, and BMI. 
Plasma adiponectin concentrations were significantly and 
positively correlated with LAVI (r=0.197, p=0.026) and E/
E’ (r=0.217, p=0.021), however, no significant association 
was found between adiponectin concentrations and LVEF. 
Adiponectin and MetS in HF patients
Among the total 128 HF patients, 43 subjects (33.6% of to-
tal, 28 males) had MetS. As presented in Table 3, gender, 
medical treatment and echocardiographic parameters were 
similar between HF patients with and without MetS. HF 
patients with MetS were significantly older than HF pa-
tients without MetS. As expected, the BMIs (p=0.003) and 
waist circumferences (p=0.003) of HF patients with MetS 
were significantly higher compared with those without MetS. 
The proportions of the patients with coronary artery disease 
(p=0.007), hypertension (p<0.001), type 2 diabetes mellitus 
Table 3. Baseline Characteristics and Echocardiographic Parameters of HF Patients without MetS and HF Pa-
tients with MetS
HF without MetS (n=85) HF with MetS (n=43) p value
Demographics
    Age (yrs)  60.0±12.6 65.3±9.6   0.018
    Male (n, %) 52 (61.2) 28 (65.1)   0.664
    BMI (kg/m
2) 23.0±3.7 25.1±3.5   0.003
    Waist circumferences (cm) 82.3±9.8 88.0±9.4   0.003
Etiologies of HF
   CAD, n (%) 32 (37.7) 27 (62.8)   0.007
   Cardiomyopathy, n ( %) 41 (48.2) 10 (23.3)   0.004
   Valvular diseases, n (%) 6 (7.1) 3 (7.0)   0.986
   Others, n (%)  6 (7.1) 3 (7.0)   0.986
Comorbidities
   Hypertension, n ( %)  20 (23.5 ) 31 (72.1) <0.001
   Diabetes, n (%)   9 (10.6) 13 (30.2) <0.001
   Dyslipidemia, n (%) 25 (29.4)   8 (18.6)   0.187
   Atrial fibrillation, n (%) 19 (22.4)   9 (20.9)   0.854
   CKD, n (%) 3 (3.5) 10 (23.3) <0.001
Medical treatment
    Diuretics, n (%)     57 (67.1%)     27 (62.8%)   0.631
    Digitalis, n (%)     21 (24.7%)     10 (23.3%)   0.856
    ACEis/ARBs, n (%)     66 (77.6%)    28 (65.1%)   0.129
    Β-blockers, n (%)     47 (52.3%)     25 (58.1%)   0.759
    CCBs, n (%)     57 (67.1%)     27 (62.8%)   0.631
Echocardiograhic parameters
    LVEF (%) 34.3±14.0   35.7±11.3   0.541
    LAVI (mL/m
2) 43.7±34.9   34.1±16.0   0.093
    E/E’ 15.1±10.0 15.5±6.6   0.807
HF, heart failure; BMI, body mass index; MetS, metabolic syndrome; CAD, coronary artery disease; CKD, chronic kidney disease; ACEis, 
angiotension converting enzyme inhibitors; ARBs, angiotension II receptor blockers; CCBs, calcium channel blockers; LVEF, left ventricu-
lar ejection fraction; LAVI, left atrial volume index; E/E’, early mitral inflow velocity to early diastolic mitral annular velocity ratio.    
Values are expressed as mean±SD. Adiponectin and Metabolic Syndrome in Heart Failure
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and insulin resistance by the 5’-adenosine monophosphate-
activated kinase signaling pathway, and decreases also free 
fatty acid concentrations by stimulating fatty acid oxidation 
in muscle.16 Thus, adiponectin may act as a potential link 
between MetS and its cardiovascular consequences. Hypo-
adiponectinemia has already been shown to be associated 
patients with MetS than in those without. The apoB and 
apoB/A1 ratio were significantly higher in HF patients with 
MetS than in those without MetS. Although hsCRP concen-
trations in HF patients with MetS were relatively higher 
than in those without MetS, this difference was not statisti-
cally significant (8.3±26.7 vs. 4.6±15.9 mg/L, p=0.433). 
In HF patients with MetS, plasma adiponectin concentra-
tions were correlated with waist circumference (r=-0.337, 
p=0.031), hemoglobin (r=-0.508, p=0.001) and E/E’ (r=0.399, 
p=0.015) (Table 5). Fig. 1 shows the trends of adiponectin 
concentrations according to MetS severity score: as MetS se-
verity scores increased, adiponectin concentrations decreased 
significantly in HF with MetS (p for trend=0.012).
DISCUSSION
The purpose of this study was to investigate whether the 
presence of MetS was associated with the degree of plasma 
adiponectin concentrations in HF patients. We demonstrat-
ed that concentrations of adiponectin were significantly 
lower in HF patients with MetS than in those without MetS. 
Furthermore, plasma adiponectin concentrations tended to 
decrease in HF patients as the number of MetS components 
increased. 
Adiponectin specifically secreted from adipose tissue is 
an adipokine. Adiponectin modulates glucose metabolism 
Table 4. Laboratory Findings for HF Patients without MetS and with MetS
HF without MetS (n=85) HF with MetS (n=43) p value
Adiponectin (μg/mL)   15.8±10.9   9.7±7.0   0.001
Cholesterol (mg/dL) 163.7±33.1 159.8±39.1   0.583
Triglyceride (mg/dL)*   112.0 (80.0-148.0)     172.0 (127.0-221.5) <0.001
HDL-cholesterol (mg/dL)   49.2±12.7 35.9±8.0 <0.001
LDL-cholesterol (mg/dL)   86.4±33.6   86.4±25.1   0.997
ApoA1 (mg/L) 134.1±23.9 114.1±16.1 <0.001
ApoB (mg/L)   70.6±19.1   84.2±27.8   0.017
ApoB/A1   0.5±0.2   0.8±0.3 <0.001
Hemoglobin (g/dL) 13.8±1.8 13.8±2.1   0.968
BUN (mg/dL) 18.0±5.7   21.4±12.3   0.034
Creatinine (mg/dL)   0.9±0.3   1.5±1.6   0.003
Albumin (mg/dL)   4.6±0.4   4.6±0.4   0.968
hsCRP(mg/L)* 0.8 (0.5-1.9) 1.8 (0.8-3.5)   0.019
Glucose, fasting (mg/dL)   99.2±16.1 148.3±70.1 <0.001
Insulin (μIU/mL)* 7.2 (4.9-8.9) 14.1 (9.1-21.3) <0.001
HOMA-IR* 1.6 (1.2-2.5) 4.0 (2.7-7.1) <0.001
HF, heart failure; MetS, metabolic syndrome; HDL, high density lipoprotein; LDL, low density lipoprotein; BUN, blood urea nitrogen; 
hsCRP, high sensitive C-reactive protein; HOMA-IR, the homeostasis model assessment of insulin resistance.
Values are expressed as mean±SD.
*Values were expressed as median (lower quartile-upper quartile), p value from Mann-Whitney U test. 
Table 5. Factors Correlated with Adiponectin Concentra-
tions in HF Patients with MetS
Variables Coefficient p value
Waist circumference (cm) -0.337 0.031
Hemoglobin (g/dL) -0.508 0.001
E/E’  0.399 0.043
HF, heart failure; MetS, metabolic syndrome; E/E’, early mitral inflow ve-
locity to early diastolic mitral annular velocity ratio. 
Fig. 1. Adiponectin concentrations according to MetS severity score. 
MetS, metabolic syndrome.
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tween adiponectin concentrations and LVEF among all the 
HF patients and with MetS, while plasma adiponectin con-
centrations correlated significantly and positively with LAVI 
and E/E’ in all HF patients. Previous study reported that ad-
iponectin had significant correlation with LA size and volume 
after adjusting confounding factors, which were associated 
with the severity and chronicity of diastolic dysfunction. The 
LV diastolic dysfunction in tissue Doppler imaging (e.g. el-
evated E/E’) presents subclinical myocardial dysfunction in 
general population and a better independent predictor than 
LVEF in systolic heart failure patients.27-30 As far as we are 
aware of, this is the first report about the association between 
adiponectin and E/E’, suggesting that adiponectin could be 
a surrogate marker of subclinical myocardial dysfunction. 
Interestingly, the correlation between adiponectin and E/E’ 
existed only in HF patients with MetS, but not in HF patients 
without MetS. This is consistent with recent reports that LV 
diastolic function and structure are associated with meta-
bolic syndrome and insulin resistance.31
The use of β-blockers might improve metabolic profiles 
by improving insulin sensitivity.32,33 Yamaji, et al.34 reported 
that carvedilol treatment in patients with HF reduced plas-
ma adiponectin levels and was associated with improvement 
of LVEF. In addition, Van Berendoncks, et al.35 showed that 
high adiponectin levels predicted poor outcomes in HF pa-
tients, but its prognostic value was significantly affected by 
β-blocker treatment. This effect of β-blocker therapy on ad-
iponectin levels was only significant in patients with lower 
BMI (<30 kg/m2). In our present study, HF patients without 
MetS who had a relatively low BMI and were treated with 
β-blockers (carvedilol and bisoprolol) had significantly low-
er adiponectin concentrations than those not given β-blockers 
(data not shown).
The limitations of this study include its relatively small 
sample size and cross-sectional design. The cross-sectional 
setting of this study made it difficult to draw causality. Fur-
ther studies will be warranted to investigate the effects of 
adiponectin on the progression of HF with MetS. Second, 
adiponectin concentrations have been found to increase in 
parallel to increases in brain natriuretic peptide (BNP) in 
HF patients.36 However, we were unfortunately unable to 
measure BNP levels in this study, therefore, we could not 
investigate the relationship between BNP levels and adipo-
nectin concentrations in HF patients with or without MetS. 
Moreover, because all the patients had been diagnosed with 
systolic HF at our heart failure clinic and they were rela-
tively non-obese, our results should be interpreted with cau-
with obesity, diabetes mellitus, insulin resistance and coro-
nary artery disease.1,2,5,6,17-19 However, the recent literatures 
suggest that HF patients have significantly higher adiponec-
tin concentrations.9,10 Although the mechanism is not clear, 
the possible reasons for high adiponectin concentrations in 
HF could be compensatory response to HF progression or 
adiponectin resistance.20,21 Takano, et al.22 also showed that 
adiponectin released from the heart may partly contribute to 
the increased adiponectin concentrations which are seen in 
the peripheral circulation of HF patients. Moreover, a high 
adiponectin concentration is a predictor of mortality of HF 
patients, independent of the risk markers of HF severity.10 
Our results suggest that the presence of MetS may have an 
effect on the adiponectin concentration in HF patients, which 
implies that adiponectin may contribute to the progression 
of HF associated with MetS.
Plasma adiponectin concentrations are related to several 
clinical variables. The present study confirmed several cor-
relations with variables including BMI, waist circumfer-
ence, triglyceride, apoB, apoB/A1 ratio, and fasting glucose 
in HF patients. ApoB/A1 ratio has been found to be associ-
ated strongly with insulin resistance.20 Park, et al.21 demon-
strated that apoB/A1 ratio was significantly correlated with 
adiponectin level in Koreans. In addition, Ingelsson, et al.23 
reported that apoB/A1 ratio was an independent risk factor 
for HF. We found in the present study that adiponectin was 
negatively associated with apoB/A1 ratio in HF patients, 
even after adjustment for age, gender, and BMI. 
Inflammation plays an important role in the pathogenesis 
and progression of HF. CRP has been found to be consis-
tently elevated in HF and MetS patients. Our study showed 
that the concentrations of hsCRP were relatively higher in 
HF patients with MetS than in those without MetS, howev-
er, it did not reach statistical significance. It might have 
been due to relatively small sample size. Adiponectin has 
been found to correlate negatively with CRP.24 We found 
that hsCRP was negatively correlated with adiponectin con-
centrations in HF patients with MetS, although not in all 
HF patients. 
Previous studies showed that adiponectin was correlated 
with cardiac geometry and function. Gustafsson, et al.25 
showed that adiponectin was inversely associated with LVEF 
in elderly men in a community-based cohort, even after ad-
justing for BMI. In addition, Unno, et al.26 reported that adi-
ponectin levels were positively associated with diastolic dys-
function in patients with hypertrophic cardiomyopathy. In 
the present study, no significant association was found be-Adiponectin and Metabolic Syndrome in Heart Failure
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tion. Third, weight loss and cardiac cachexia cause signifi-
cant increases in circulating adiponectin concentrations.37 
We had no information as to whether weight loss occurred 
in our HF patients. 
In conclusion, we have shown that plasma adiponectin 
concentrations were significantly lower in HF patients with 
MetS than in those without MetS, and were significantly 
correlated with hsCRP and E/E’ in HF patients with MetS. 
Also, there is a tendency toward decreased plasma adiponec-
tin concentrations according to the severity score of MetS. 
This study implies that decreased plasma concentrations of 
adiponectin in HF patients with MetS are associated with 
inflammation and abnormal diastolic function, which could 
lead to progression of HF.
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